Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection (NCT06112353) | Clinical Trial Compass
RecruitingPhase 4
Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection
United States128 participantsStarted 2024-04-17
Plain-language summary
The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (GI-2 recovery) following bowel resection surgery
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 18 or older
* Laparoscopic bowel resection surgery under general anesthesia with nondepolarizing neuromuscular blockade with rocuronium or vecuronium, and requiring inpatient admission
Exclusion Criteria:
* Allergy to Rocuronium, Vecuronium, or Sugammadex
* Bowel resection surgery requiring an ostomy
* No severe valvulopathy, no systolic heart failure with reduced ejection fraction (HFrEF), no coronary artery disease with positive stress test for ischemic regional wall motion abnormality
* No autoimmune pulmonary disease, no severe pulmonary fibrosis, no severe pulmonary hypertension, no COPD with requirement of home oxygen, no pulmonary cancer of primary or metastatic origin
* Creatinine Clearance (CrCl) of less than 30
* Pregnancy
* Incapable of providing consent or understanding the research project